We are live on ! Find out more
PJP icon

Invesco Pharmaceuticals ETF

108 hedge funds and large institutions have $71M invested in Invesco Pharmaceuticals ETF in 2025 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 30 increasing their positions, 17 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

214% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 7

96% more capital inflows, than outflows

Capital inflows: $9.5M | Capital outflows: $4.87M

76% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 17

15% more funds holding

Funds holding: 94 → 108 (+14)

0.31% more ownership

Funds ownership: 22.25% → 22.56% (+0.31%)

Holders
108
Holders Change
+14
Holders Change %
+14.89%
% of All Funds
1.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
30
Reduced
17
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

PJP Hedge Fund Activity: Q4 2025 in Review

108 of the 8,313 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q4 2025, worth a combined $71M — up 20% from $59.1M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new PJP positions and 7 closed out — a net gain of 15 holders — while 30 added to existing stakes and 17 trimmed.

The largest buyer was Wells Fargo, adding an estimated $1.87M. The largest seller was Goldman Sachs, exiting entirely with an estimated $2.15M sold.

  • 108 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q4 2025, up from 94 in Q3 2025.
  • Funds reported $71M of Invesco Pharmaceuticals ETF stock for Q4 2025, up 20% quarter-over-quarter.
  • 22 funds opened new Invesco Pharmaceuticals ETF positions in Q4 2025 and 7 closed out, a net change of +15 holders.
  • The largest Invesco Pharmaceuticals ETF buyer in Q4 2025 was Wells Fargo, an estimated $1.87M added.
  • The largest Invesco Pharmaceuticals ETF seller in Q4 2025 was Goldman Sachs, an estimated $2.15M sold.

Based on aggregated 13F filings for Q4 2025.